- Company
- Zolgensma & Kymriah will be entered the Korean market
- by Eo, Yun-Ho May 8, 2020 06:34am
- Two very expensive new drugs by Novartis enter the Korean market. According to a related industry, Novartis Korea submitted an application for the approval of a treatment for Spinal Muscular Atrophy (SMA), Zolgensma (Onasemnogene abeparvovec) & CAR-T (Chimeric Antigen Receptor T cells) cell gene therapy, Kymriah (Tisagenlecleucel) earlier
- Company
- Jeil got a domestic exclusive promotion for Amitiza
- by Lee, Seok-Jun May 8, 2020 06:34am
- Jeil distributes FDA-approved constipation drugs in Korea. Jeil announced on the 6th that it has signed an exclusive promotional contract (distribution, marketing, and sales rights) in Korea with Amitiza soft capsule (Lubiprostone), a chronic constipation treatment for Takeda. Amitiza received FDA approval in 2006. In Korea, the approva
- Company
- Pharmaceutical companies ended telecommuting
- by Kim, Jin-Gu May 7, 2020 06:02am
- The 45-day “social distance campaign” ended. The government has announced that instead of ending social distance on the 5th, it will start “distancing in daily life” from the 6th. According to the government guidelines revision, pharmaceutical companies are also returning to normal business one after another. Most pharmaceutical companies
- Company
- Reimbursement talks on first CMV prophylaxis soon to begin
- by Eo, Yun-Ho May 7, 2020 06:01am
- The reimbursement approval talk is about to get started for Prevymis, a medicine to prevent cytomegalovirus (CMV) infection in stem cell transplant recipient. Korean pharmaceutical industry sources reported MSD’s Prevymis (letemovir) that was passed by Economic Evaluation Subcommittee last month would be deliberated by Health Insurance
- Company
- Temptation to reduce the cost of DMF
- by Kim, Jin-Gu May 7, 2020 06:01am
- About 7 out of 10 DMF that pharmaceutical companies have registered for use are from India and China. Compared to 10 years ago, the share of DMF in India and China is also increasing significantly. It is an analysis that pharmaceutical companies have increased demand for inexpensive Indian·Chinese drug products to cut costs. According to the MF
- Company
- Cancer Committee lets down both Keytruda and Tagrisso
- by Eo, Yun-Ho May 7, 2020 06:01am
- Apparently, neither one of Keytruda and Tagrisso won the Cancer Deliberation Committee’s nod. According to the pharmaceutical industry sources on May 1, Health Insurance Review and Assessment Service (HIRA) Cancer Deliberation Committee convened a meeting after postponing it twice due to COVID-19, and decided to ‘defer’ the reimbursem
- Company
- Toujeo passed DC of big 5 general hospitals
- by Eo, Yun-Ho May 6, 2020 06:32am
- Next-generation insulin Toujeo can be prescribed at the Big 5 General Hospitals. According to the related industry, 'Toujeo inj Solostar (gene recombination insulin Glargine)' recently passed DC of Seoul National University Hospital, Seoul St. Mary's Hospital, Samsung Medical Center, and AMC including Severance Hospital. In addition, it
- Company
- 902 trials around the world seeking for COVID-19 treatment
- by Kim, Jin-Gu May 6, 2020 06:32am
- 100 days have passed since the first confirmed case of COVID-19 was reported in Korea. While Korea seems to have flattened the curve, other countries like the U.S. and European countries are still enforcing strict emergency orders. Meanwhile, the global community is unprecedentedly speeding up the treatment and vaccine development. As of Apr
- Company
- General hospitals ready to prescribe Verzenio
- by Eo, Yun-Ho Apr 28, 2020 06:24am
- The general hospitals in Korea have started entering the anticancer treatment Verzenio’s prescription code. According to pharmaceutical industry sources, drug committees at major general hospitals like Seoul National University Hospital, National Cancer Center, Ajou University Hospital and Chonnam National University Hwasun Hospital have
- Company
- Boryung records new quarterly operating profit
- by Chon, Seung-Hyun Apr 28, 2020 06:23am
- Boryung showed good results in the first quarter. Despite COVID-19, operating profit was the largest ever. Sales also rose from last year. The self-developed drug 'Kanarb Family' led the improvement. Boryung announced on the 24th that its operating profit in the first quarter increased by 42.1% year-on-year to &8361;13.4 billion. During t
